Variation in the expression of alleles is common and contributes to human variation (1) (2) (3) . In addition, altered germline expression of alleles due to genetic (4 -7 ) and epigenetic (8, 9 ) mechanisms has been shown to play a pathogenic role in monogenic diseases. Altered allele expression due to variation in gene copy number or to other mechanisms that affect the transcription and/or stability of individual genes has been hypothesized to be one of the main mechanisms involved in predisposition to polygenic disease (10, 11 ) . These considerations suggest that altered constitutive production of germline transcripts represents a powerful marker for analyzing genetic or epigenetic predisposition to cancer or other diseases. Accordingly, previous studies have shown that primer-extension analysis of germline transcripts detects pathogenic alterations in gene expression in a relevant fraction of cases that test negative with conventional mutational analyses (5-7, 12, 13 ) .
Considering the relevance of allele-specific expression (ASE) 7 in physiological and pathologic processes, it is important to develop practical methods for the screening of candidate genes. Such methods may also be helpful for orthogonal validation of ASE measure-ments obtained with powerful but expensive methods, such as those used in genome-wide analyses (2, 14 -16 ) .
Several methods use primer extension for ASE analysis. Extended primers may be quantified via labeling with radioactive (6 ) or fluorescent (12 ) compounds and subsequent resolution by electrophoresis. Mass spectrometry is another technique that can be used to distinguish and quantify extended primers (17, 18 ) . Pyrosequencing can also be used for ASE analysis (16 ) . All of these methods are very accurate, but they can be expensive, especially for small-scale experiments.
Denaturing HPLC (DHPLC) instruments are available in many laboratories and are frequently devoted to mutational analysis. DHPLC-based primerextension assays were initially developed to genotype pools of genomic DNA (gDNA) (19, 20 ) , and unlabeled reactions were used in these assays. Tournier et al. (21 ) subsequently published a proof-of-principle study that demonstrated the feasibility of DHPLCbased ASE analysis by cDNA genotyping with unlabeled reagents. This study analyzed a single-nucleotide polymorphism (SNP) (rs1799977:GϾA), the most frequently occurring variant within exon 8 of MLH1, and distinguished primer-extension products that differed in sequence by only the incorporated dideoxynucleotide (21 ). This experimental design may limit a wider application to other SNPs, however, because DHPLC may fail in some cases to discriminate extended primers that differ in sequence by only a single nucleotide. Moreover, the signals derived from the 2 alleles in the assay of Tournier et al. (21 ) for a single allelic marker fortuitously had comparable intensities in control individuals; thus, normalization of the cDNA data was unnecessary for that particular assay. The lack of normalization represents a problem in the general application of the method, however, because previous studies of gDNA with different markers have shown that templates with equimolar allelic ratios often do not yield allelic signals of comparable intensities (20 ) . This bias may hamper the interpretation of results and therefore should be taken into account in developing novel cDNA assays. To avoid potential problems with the application of primer-extension assays, we chose to measure ASE by a different primer extension-based method that uses a single dideoxynucleotide. With this method, the products of primer extensions corresponding to the 2 alleles differ in both length and sequence, which should facilitate DHPLC discrimination of any sequence variant. In line with this prediction, we developed 5 different DHPLC-based assays that target frequent or rare sequence variants of 2 mismatch repair genes. We also discuss some issues to be taken into account in the development and interpretation of cDNA primer-extension assays, including the normalization of data. 
Materials and Methods

PATIENTS
NUCLEIC ACID EXTRACTION AND cDNA SYNTHESIS
Peripheral blood lymphocytes or lymphoblastoid Epstein-Barr virus-transformed cell lines were used as the source of nucleic acids. Genomic DNA was extracted with the QIAamp DNA Blood Mini Kit (Qiagen). Total RNA was isolated with the acid guanidinium isothiocyanate-phenol-chloroform extraction method (22 ) . The concentration and purity of extracted RNA was measured with a GeneQuant pro spectrophotometer (Amersham Biosciences/GE Healthcare) in an "ultra microvolume" cell. To eliminate residual genomic DNA, we treated RNA samples with DNase I (Invitrogen). We used 1.3-6 g of total RNA for cDNA synthesis, because preliminary experiments in control individuals indicated that smaller amounts of RNA generated results that were poorly reproducible in subsequent primer-extension assays. RNAs were incubated at 70°C for 10 min with 2.5 mol/L of random hexamer and then cooled on ice. First-strand synthesis was then carried out in a 20-L volume with the Superscript II Reverse Transcriptase kit (Invitrogen) according to the manufacturer's specifications.
PRIMER-EXTENSION REACTIONS
Primer-extension assays were performed with PCRamplified gDNA and cDNA templates that were treated with exonuclease I and shrimp alkaline phosphatase (USB Corporation) at 37°C for 20 min and then heated at 80°C for 20 min to inactivate the enzymes.
The reactions were performed in a 20-L volume containing 1ϫ Thermo Sequenase Reaction Buffer, 0.5 U Thermo Sequenase (Amersham Biosciences/GE Healthcare), 40 ng of treated PCR product annealed with 25 pmol of the appropriate HPLC-purified primer (Sigma-Genosys/Sigma-Aldrich), 0.05 mmol/L of a single dideoxyribonucleoside triphosphate (ddNTP) specific for each primer-extension assay (ddATP for c.655GϾA and c.965GϾA assays; ddCTP for c.1852-3AAϾGG, c.1852-4delAAG, and c.2306 -8delCTT; Roche Diagnostics), and 0.05 mmol/L of each of the 3 complementary deoxyribonucleoside triphosphates (dNTPs). Primer extensions were performed in a GeneAmp PCR System 9700 thermal cycler (Applied Biosystems) with the following thermal profile: initial denaturation at 94°C for 2 min; 50 cycles of denaturation at 94°C for 5 s, annealing at 43°C for 5 s, and extension at 60°C for 5 s; and final denaturation at 94°C for 30 s. Further experimental details, including the sequences of primers used for amplification and primer extension, are presented in Table 1 of the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol55/issue9.
DHPLC ANALYSIS
Ten microliters of the product of the primer-extension reaction was resolved without further purification or denaturation on a WAVE 1100 DHPLC instrument (Transgenomic) held at a constant oven temperature of 80°C. We selected the Oligo Purification application and the option "15-50 bases, no fluorescent tag" of WAVEMAKER Software Version 4.1 (Transgenomic) for the analysis. Samples were eluted from a Transgenomic DNASep cartridge column at a constant flow rate of 0.9 mL/min over a linear acetonitrile gradient obtained by mixing 2 solutions: buffer A (0.1 mol/L triethylammonium acetate, pH 7.0) and buffer B (0.1 mol/L triethylammonium acetate and 250 mL/L acetonitrile, pH 7.0). The initial and final proportions of buffer B in the gradient were 18% and 35%, respectively, for a run time of 11.2 min. Primer-extension peaks were detected at 260 nm with a UV detector, and the data were analyzed with WAVEMAKER software. Relative production of gene transcripts was estimated by comparing the heights of the peaks corresponding to the 2 alleles obtained by primer extension with cDNA templates. The mean ratio obtained by analyzing gDNA templates for the corresponding variant was used to normalize cDNAs. We used the following equation for normalization: Normalized cDNA Ratio ϭ cDNA Ratio/Mean gDNA Ratio.
Results
For preliminary validation of the DHPLC primerextension method, we analyzed MLH1 variant c.655GϾA (rs1799977:GϾA). This allele recurs frequently in our population (minor allele frequency, 0.46), allowing primer-extension analysis of multiple heterozygous individuals. We initially tested the reproducibility of the method with gDNA from different heterozygous individuals (Table 1) . Replicate determinations for the same individuals yielded CVs of 0.12%-8.5% (Table 1 , intraindividual determinations). With gDNA templates from different heterozygous individuals, the mean ratio of the peak heights corresponding to the 2 alleles was 0.76 (range, 0.72-0.82; SD, 0.032), and the CV was 4.2% (Table 1 , interindividual determinations). The CVs were comparable to those previously reported for other gDNA-based primerextension assays (20 ) . In heterozygous individuals, the gDNA allelic ratio is expected to yield values close to 1, assuming an equal representation of the 2 alleles; however, another laboratory (20 ) previously found that mean peak ratios for gDNA from heterozygous individuals were often different from the expected value of 1, with an up to 2-fold difference in peak heights. After this preliminary validation with gDNA, we validated the assay with cDNA templates from 19 control individuals who had available RNA and were heterozygous for the rs1799977:GϾA marker (Table 2 ). When we used this marker, the mean peak ratio for cDNA from controls was 0.79 (SD, 0.09) ( Table 2) . As was also observed in gDNA analyses, the mean peak ratio observed in heterozygous controls was different from the expected value of 1. To resolve the problem of the apparent unequal representation of alleles, we normalized primer-extension data derived from cDNA with the mean peak ratio obtained with gDNA from heterozygous individuals. This normalization generated a mean cDNA allelic ratio of 1.04 (SD, 0.11), which is close to the expected value of 1 ( Table 2 ). The CVs derived from multiple (3-8 ) intraindividual measurements for cDNAs from the 19 control individuals ranged from 2.4% to 16% (Table 2) , with a mean CV of 10%. Measurements of MLH1 allelic ratios in cDNA from different control individuals showed narrow interindividual variation, which was reflected by normalized allelic ratios of 0.87-1.23.
In addition to validating the method with the frequent SNP rs1799977:GϾA, we also developed 4 addi-tional DHPLC primer-extension assays that exploited infrequent MLH1 or MSH2 markers detected in HNPCC patients who were studied in our laboratory and had RNA available. We initially tested the reproducibility of the 4 additional assays with gDNA templates from the 4 heterozygous individuals (see Table 2 in the online Data Supplement). The mean ratio of the allele peak heights with gDNA templates for the 4 assays was 0.98 for the c.1852-3AAϾGC variant (case 2916), 0.87 for the c.1852-4delAAG variant (case GDLG29), 1.02 for the c.2306 -8delCTT variant (case 2504), and 0.97 for the c.965GϾA variant (case GE9903). Intraindividual CVs ranged from 4.6% to 12% ( Table 2 in the online Data Supplement). Fig. 1 shows representative chromatograms corresponding to cDNA and gDNA primer-extension analyses for the 5 assays we developed. Histograms in the figure display the mean relative expression of the 2 alleles, normalized with gDNA. One patient (no. 2916) showed a marked imbalance in MLH1 expression with the rs1799977:GϾA allelic marker in exon 8 (normalized mean allelic ratio, 4.93; Table 3 in the online Data Supplement), with an approximately 80% lower expression of the c.655A allele (Fig. 1A) . Interestingly, this patient was also heterozygous for an additional sequence variant (c.1852-3AAϾGC) in exon 16 of the same gene. The presence of these 2 markers allowed independent assessment of relative MLH1 expression with 2 different assays. As shown in Fig. 1B , the independent assay confirmed the marked imbalance in the relative expression of MLH1 alleles (normalized mean allelic ratio, 5.62; Table 3 in the online Data Supplement), with an approximately 80% lower expression of the c.1852-3AA allele. Sequencing analysis of the affected mother revealed that she was homozygous for both the c.655A and c.1852-3AA variants. This result indicated that both variants with reduced expression in patient no. 2916 were inherited from the mother and thus cosegregated on the same allele. Unfortunately, an analysis of the relative production of transcripts could not be performed in other affected or at-risk siblings because either RNA or heterozygous markers were unavailable for these individuals. One additional patient (no. GDLG29), who was heterozygous for the rare inframe variant c.1852-4delAAG (exon 16), had a modest imbalance in the relative expression of MLH1 alleles, with a 30% lower expression of the allele carrying the wild-type marker (Fig. 1C) . This modest imbalance was reproducible in 4 independent determinations (normalized mean allelic ratio, 1.40; Table 3 in the on- line Data Supplement). Because slight sequence differences between primer-extension templates have the potential to affect normalization and because the primers originally used for gDNA or cDNA amplification were different, we also designed an alternative primerextension assay based on cDNA and gDNA templates with identical sequences (Table 1 in the online Data Supplement). This independent assay yielded a normalized mean allelic ratio of 1.33 in 4 independent determinations. Thus, the 2 assays yielded comparable results, confirming that this patient had a modestly imbalanced MLH1 allele expression. This imbalance was just greater than 2 SDs from the mean allelic ratio observed in controls with the rs1799977:GϾA allelic marker ( Table 2 ). Two of the additional patients analyzed (nos. 2504 and GE9903), who were heterozygous for MLH1 c.2306 -8delCTT (exon 19, 3Ј untranslated region) and MSH2 c.965GϾA sequence variants, respectively, did not display variation in the relative expression of the corresponding alleles (Fig. 1, D and E) . The normalized mean allelic ratios were 1.09 and 1.08 for patients 2504 and GE9903, respectively ( Table 3 in the online Data Supplement).
Overall, the measures of intraindividual cDNA allelic ratios of controls and cases were highly reproducible for the 5 independent assays developed for the 2 mismatch repair genes (Table 2 and Supplemental  Data Table 3) , with a mean CV of 8.8% (range, 2.4%-16%).
Discussion
Analysis of ASE is an important task in the study of both physiological and pathologic conditions. We developed and validated a method for the study of ASE based on DHPLC analysis of primer-extension products that differ in both length and sequence. Our application of this method in 5 different assays showed that this approach is practical, flexible, and reproducible.
The method was initially validated with gDNA and cDNA from control individuals. In agreement with a previous gDNA-based study (20 ) , the intra-and interindividual CVs obtained with gDNA from heterozygous individuals in the present study confirmed the high reproducibility of this method. We also observed low intraindividual CVs in both controls and patients when we applied the method to cDNA measurements. The availability of the frequently occurring MLH1 SNP rs1799977:GϾA allowed us to measure interindividual variation in allele expression for this gene in the control population. In line with a previous study (21 ), we observed a narrow variation in interindividual expression of MLH1 alleles in control individuals, which likely reflects physiological variation in relative allele expression.
As has previously been noted with different DHPLC applications (20, 21, 23, 24 ) , chromatographic profiles sometimes did not reach baseline between eluting peaks. Considering that an uneven baseline might affect the calculation of peak areas, we observed, as have previous studies (23, 24 ) , that the use of peak heights rather than peak areas allowed a more reliable estimate of relative allele expression, which was reflected in the smaller CVs (Table 4 in the online Data Supplement).
Another issue raised by the present study is the normalization of ASE data. With gDNA from different heterozygous individuals, we observed that the allelic peak ratio could be reproducibly different from the expected value of 1. This bias in gDNA peak ratios was previously reported in different primerextension assays that used either 1 or 2 ddNTPs in DHPLC-based detection (20 ) or in automated sequence-based detection (25 ) . The high reproducibility of the assays indicates that the discrepancy is not due to the reliability of the methods. In this regard, primer-extension assays that use either 1 or 2 different ddNTPs may yield an up to 2-fold apparent distortion in allelic ratios with gDNA from heterozygous control individuals (20 ) . As suggested by previous studies (20, 25 ) , possible explanations for the apparent distortion of the allelic ratio when gDNA from heterozygous individuals is used could be differential PCR amplification of alleles, differential efficiency of incorporation of the respective dNTPs/ ddNTPs for each primer-extension reaction, and differences in the absorbances of 2 primer-extension products differing in sequence and/or length. In cDNA-based assays, it is important to circumvent this apparent distortion in allelic ratio because it affects interpretation of the data. We showed that normalization of cDNA allelic ratios with the mean gDNA allelic ratio obtained for heterozygous control individuals corrected the apparent distortion in allele expression. Conversely, without normalization, the apparent distortion of the allelic ratio observed in samples with equimolar representation of alleles may yield results that could be erroneously interpreted as caused by imbalanced allele expression. Ideally, normalization should be performed with templates obtained by mixing equal amounts of DNA representing the 2 alleles; however, it is more convenient for common variants to use gDNA from several heterozygotes for which equimolar representation of the alleles is expected. In the case of rare variants, gDNA from a single heterozygote could be used for normalization, provided that extended rearrangements that could affect the copy number of the gene to be tested can be excluded. Another issue to consider in interpreting potentially pathogenic imbalanced allele expression is any observed variation in allele expression among control individuals for the gene of interest. Such variation has been shown to vary widely among different genes, with some genes showing narrow variation and others, such as imprinted genes, showing a Ͼ4-fold difference in ASE (1, 2 ) . Both the present study and a previous study (21 ) showed that MLH1 has a narrow variation in allele expression. Two of the patients in our study showed imbalanced MLH1 allele expression. One had a marked imbalance that was clearly outside the range of variation observed in controls and was likely pathogenic. The other patient had a modest degree of imbalance, which, because the imbalance was borderline compared with the variation in allele expression observed in control individuals, is unlikely to play a major pathogenic role in this HNPCC patient. A pathogenic role cannot be excluded, however, because modest degrees of unbalanced allele expression demonstrated for other genes involved in colorectal carcinogenesis have been shown to have the potential to contribute to a cancer predisposition (11, 26 ) .
The quantity and quality of the RNA are among the factors that may interfere with correctly estimating relative allele expression. Low RNA quality or quantity may limit the number of cDNA templates that can be subsequently amplified and used for measuring relative expression by primer extension. Under these conditions, one allele may be underrepresented in the pool of cDNA templates used for PCR amplification, generating primer-extension results erroneously interpreted as unbalanced allele expression. Low production of the transcript of interest in the tissue used as the RNA source may limit the pool of cDNA templates. Thus, in addition to RNA quantity and quality, the relative abundance of the transcript may also affect the measurement of relative allele expression. In our experience, however, artifacts due to limiting amounts of the transcript of interest are easily recognized because cDNA templates in such cases require Ͼ33-35 PCR cycles to generate products that are visible on an ethidium bromide-stained gel. Moreover, limiting amounts of templates requiring Ͼ33-35 PCR cycles will cause erratic amplification of single alleles or an apparently imbalanced allele representation that is not reproducible in replicated experiments with independent RNA samples.
The interpretation of a single primer-extension assay may also be hampered by artifacts generated by nucleotide substitutions in the template. Such nucleotide variants may interfere with the annealing of oligonucleotides (used for PCR amplification or primer extension) to templates derived from one of the alleles, generating a false indication of unbalanced expression. Avoiding these potential artifacts requires sequencing of the regions where the amplification and primer-extension primers anneal to the template. The 4 patients analyzed in our study had undergone sequencing analysis and were negative for pathogenic mutations. In addition, we used 2 different assays to confirm the unbalanced allele expression observed in patients 2916 and GDLG29. The use of independent assays adds confidence to the results, because potentially interfering factors are unlikely to affect the same allele in different assays that use independent sets of primers.
A limitation of the method is that it can be applied only to individuals heterozygous for a sequence variant of the gene of interest. This limitation may be especially relevant if this gene carries only rare polymorphisms, because in such cases most individuals would not be suitable for the assay.
Inconclusion,wedevelopedandvalidatedaDHPLCbased nonfluorescent primer-extension method for the analysis of the relative production of transcripts that could be useful for the diagnosis of inherited disorders. This approach could be helpful in the analysis of cases in which conventional screening has failed to detect pathogenic mutations in candidate genes. Moreover, DHPLC-based primer extension can be used to obtain orthogonal validation of putative alterations in ASE revealed by other methods, such as those used for genome-wide analyses, to provide a cost-effective strategy for detection or independent confirmation of ASE, particularly in small-scale experiments.
